The medical device testing firm has expanded its lab network by acquiring WuXi AppTec’s US-based facilities.
NAMSA, a US-based medtech testing, clinical, and regulatory consulting firm, announced that it acquired WuXi AppTec’s US medical device testing operations on Feb 28.
The acquisition brings together two companies specializing in medical device biological safety testing, serving more than 4,000 manufacturers worldwide.
“Together, we now have unmatched scientific expertise in biocompatibility, microbiology, preclinical and extractables, and leachables testing. With the addition of WuXi AppTec medical device testing facilities in the US, we now have more scientists, more lab capacity, and more expertise with a wider variety of medical devices than any other company,” says Lisa Olson, NAMSA senior vice president of global laboratory services in a release. “This combined expertise will continue to enable our work with clients to develop testing and consulting strategies tailored to their specific device and regulatory pathways.”
NAMSA has been expanding its reach in recent years as it continues to diversify its offering beyond biological safety testing. Since 2021, the company has acquired no fewer than six companies focused on preclinical or clinical research.
“This acquisition is part of our larger strategy to broaden our service offering and solidify our position as the go-to resource for manufacturers bringing new life-saving technologies to market while upholding the same high standards of client-focused service you have come to expect from NAMSA,” says Brian Smith, NAMSA’s recently appointed CEO, in a release.
Summary:
NAMSA, a medical device testing and regulatory consulting firm, has acquired WuXi AppTec’s US-based medical device testing operations. The move expands NAMSA’s laboratory capacity and expertise in areas such as biocompatibility, microbiology, and regulatory testing. The acquisition is part of NAMSA’s continued expansion in contract research services, following a series of acquisitions in recent years aimed at broadening its role in medical device testing and compliance.
Key Takeaways:
- NAMSA Acquires US Testing Operations – The medical device testing firm has expanded its lab network by acquiring WuXi AppTec’s US-based facilities.
- Increased Capacity for Device Testing – The acquisition adds resources in biocompatibility, microbiology, and regulatory testing for medical device manufacturers.
- Part of Ongoing Expansion Strategy – The deal continues NAMSA’s efforts to grow its contract research and regulatory consulting services for the MedTech industry.
ID 353659539 | Acquisition © Ramirezom | Dreamstime.com
